S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
NASDAQ:NKTR

Nektar Therapeutics - NKTR Stock Forecast, Price & News

$0.93
-0.05 (-5.10%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.92
$1.01
50-Day Range
$0.93
$3.15
52-Week Range
$0.92
$6.40
Volume
8.54 million shs
Average Volume
3.60 million shs
Market Capitalization
$176.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.08

Nektar Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
1.50 Rating Score
Upside/​Downside
231.1% Upside
$3.08 Price Target
Short Interest
Healthy
4.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.87mentions of Nektar Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$121,158 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

195th out of 988 stocks

Pharmaceutical Preparations Industry

75th out of 482 stocks


NKTR stock logo

About Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Stock News Headlines

Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Analyst Ratings for Nektar Therapeutics
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Why Is Nektar Therapeutics (NKTR) Stock Down 39% Today?
Nektar Therapeutics: Recovery Seems To Be A Mirage
SVB Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates
Nektar Therapeutics Q3 Loss decreases, beats estimates
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Company Calendar

Last Earnings
2/28/2023
Today
3/20/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
740
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$3.08
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+231.1%
Consensus Rating
Hold
Rating Score (0-4)
1.50
Research Coverage
6 Analysts

Profitability

Net Income
$-368,200,000.00
Net Margins
-399.98%
Pretax Margin
-396.48%

Debt

Sales & Book Value

Annual Sales
$92.06 million
Book Value
$1.95 per share

Miscellaneous

Free Float
182,839,000
Market Cap
$176.24 million
Optionable
Optionable
Beta
1.10

Social Links


Key Executives

  • Howard W. RobinHoward W. Robin
    President, Chief Executive Officer & Director
  • Jillian B. ThomsenJillian B. Thomsen
    Chief Financial Officer & Senior Vice President
  • Jonathan ZalevskyJonathan Zalevsky
    Chief Research & Development Officer
  • Brian L. Kotzin
    Chief Medical Officer & Senior Vice President
  • Mary Tagliaferri
    Chief Development Officer & Senior Vice President













NKTR Stock - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 3 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price forecast for 2023?

6 brokerages have issued 12-month target prices for Nektar Therapeutics' shares. Their NKTR share price forecasts range from $1.50 to $6.00. On average, they predict the company's share price to reach $3.08 in the next twelve months. This suggests a possible upside of 231.1% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2023?

Nektar Therapeutics' stock was trading at $2.26 at the beginning of 2023. Since then, NKTR shares have decreased by 58.8% and is now trading at $0.9313.
View the best growth stocks for 2023 here
.

Are investors shorting Nektar Therapeutics?

Nektar Therapeutics saw a decline in short interest during the month of February. As of February 28th, there was short interest totaling 8,750,000 shares, a decline of 11.8% from the February 13th total of 9,920,000 shares. Based on an average trading volume of 1,960,000 shares, the short-interest ratio is currently 4.5 days.
View Nektar Therapeutics' Short Interest
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings data on Tuesday, February, 28th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. The biopharmaceutical company had revenue of $22.02 million for the quarter, compared to the consensus estimate of $22.21 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 76.92% and a negative net margin of 399.98%. The business's revenue was down 11.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.79) EPS.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (1.83%), Dimensional Fund Advisors LP (1.36%), Norges Bank (0.90%), Morgan Stanley (0.87%), Charles Schwab Investment Management Inc. (0.73%) and Principal Financial Group Inc. (0.63%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, R Scott Greer and Robert Chess.
View institutional ownership trends
.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $0.93.

How much money does Nektar Therapeutics make?

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $176.24 million and generates $92.06 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

The company employs 740 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.

This page (NASDAQ:NKTR) was last updated on 3/21/2023 by MarketBeat.com Staff